A conditionally replicative adenovirus, CRAd-S-pK7, can target endometriosis with a cell-killing effect.

BACKGROUND Novel therapeutic approaches for endometriosis based on molecular strategies may prove to be useful. Conditionally replicative adenoviruses (CRAds) are designed to exploit key differences between target and normal cells. The wild-type adenovirus (Adwt) promoter can be replaced by tissue-specific promoters, allowing viral replication only in target cells. Viral infectivity can be enhanced by altering Ad tropism via fiber modification. We investigated whether CRAds can be used to target endometriosis and determined the most efficient transcriptional- and transductional-targeting strategy. METHODS An in vitro study was carried out using human endometriotic cell lines, 11Z (epithelial) and 22B (stromal), normal human ovarian surface epithelial cell line (NOSE006) and primary human endometriosis cells. A total of 9 promoters and 12 Ad tropism modifications were screened by means of a luciferase reporter assay. From this screening data, three CRAds (CRAd-S-pK7, CRAd-S-RGD, CRAd-S-F5/3sigma1, all incorporating the survivin promoter but with different fiber modifications) were selected to perform experiments using Adwt and a replication-deficient virus as controls. CRAds were constructed using a plasmid recombination system. Viral-binding capacity, rates of entry and DNA replication were evaluated by quantitative real-time PCR of viral genome copy. Cell-killing effects were determined by crystal violet staining and a cell viability assay for different concentrations of viral particles per cell. RESULTS Comparison of promoters demonstrated that the survivin promoter exhibited the highest induction in both endometriotic cell lines. Among the fiber-modified viruses, the polylysine modification (pK7) showed the best infection enhancement. CRAd-S-pK7 was validated as the optimal CRAd to target endometriosis in terms of binding ability, entry kinetics, DNA replication and cell-killing effect. CRAd-S-pK7 also exhibited a high level of DNA replication in primary endometriosis cells. CONCLUSIONS CRAd-S-pK7 has the best infection and cell-killing effect in the context of endometriosis. It could prove to be a useful novel method to target refractory cases of endometriosis.

[1]  D. Curiel,et al.  Treatment of endometriosis with a VEGF-targeted conditionally replicative adenovirus. , 2010, Fertility and sterility.

[2]  L. Hartmann,et al.  Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. , 2010, Cancer research.

[3]  Hongjie Wang,et al.  A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy. , 2010, Blood.

[4]  J. Geng,et al.  Increased immunoreactivity to SLIT/ROBO1 in ovarian endometriomas: a likely constituent biomarker for recurrence. , 2009, The American journal of pathology.

[5]  D. E. Machado,et al.  Composition of sulfated glycosaminoglycans and immunodistribution of chondroitin sulfate in deeply infiltrating endometriosis affecting the rectosigmoid. , 2009, Micron.

[6]  F. Nezhat,et al.  The relationship of endometriosis and ovarian malignancy: a review. , 2008, Fertility and sterility.

[7]  A. Starzinski-Powitz,et al.  Gene expression profiles and functional characterization of human immortalized endometriotic epithelial and stromal cells. , 2008, Fertility and sterility.

[8]  D. Curiel,et al.  Toward gene therapy of endometriosis: transductional and transcriptional targeting of adenoviral vectors to endometriosis cells. , 2008, American journal of obstetrics and gynecology.

[9]  D. Hardy,et al.  Inflammatory status influences aromatase and steroid receptor expression in endometriosis. , 2008, Endocrinology.

[10]  C. Jingting,et al.  Expression of heparanase and angiopoietin-2 in patients with endometriosis. , 2008, European journal of obstetrics, gynecology, and reproductive biology.

[11]  P. Gattuso,et al.  Immunohistochemical detection of heparanase-1 expression in eutopic and ectopic endometrium from women with endometriosis. , 2007, Fertility and sterility.

[12]  N. Tanaka,et al.  Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. , 2007, Human pathology.

[13]  A. Rivera,et al.  Targeting adenovirus to CD80 and CD86 receptors increases gene transfer efficiency to malignant glioma cells. , 2007, Journal of neurosurgery.

[14]  A. Rivera,et al.  Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. , 2007, Human gene therapy.

[15]  A. Al-Hendy,et al.  Toward gene therapy of endometriosis: adenovirus-mediated delivery of dominant negative estrogen receptor genes inhibits cell proliferation, reduces cytokine production, and induces apoptosis of endometriotic cells. , 2007, Fertility and sterility.

[16]  P. Fisher,et al.  A Mosaic Fiber Adenovirus Serotype 5 Vector Containing Reovirus σ1 and Adenovirus Serotype 3 Knob Fibers Increases Transduction in an Ovarian Cancer Ex vivo System via a Coxsackie and Adenovirus Receptor–Independent Pathway , 2007, Clinical Cancer Research.

[17]  J. Marks,et al.  Regulation of the metastasis suppressor gene MKK4 in ovarian cancer. , 2007, Gynecologic oncology.

[18]  A. Rivera,et al.  Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma. , 2006, International journal of oncology.

[19]  D. Curiel,et al.  A new targeting approach for breast cancer gene therapy using the heparanase promoter. , 2006, Cancer letters.

[20]  Y. Terai,et al.  Transcriptional expression of survivin and its splice variants in endometriosis. , 2006, Molecular human reproduction.

[21]  I. Ulasov,et al.  CD46 represents a target for adenoviral gene therapy of malignant glioma. , 2006, Human gene therapy.

[22]  M. Lamfers,et al.  The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. , 2006, Journal of neurosurgery.

[23]  J. Mathis,et al.  A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy , 2005, Gene Therapy.

[24]  A. Ciavattini,et al.  Endothelial cell survivin is involved in the growth of ovarian endometriotic cysts. , 2005, Anticancer research.

[25]  D. Curiel,et al.  Reovirus sigma1 fiber incorporated into adenovirus serotype 5 enhances infectivity via a CAR-independent pathway. , 2005, Biochemical and biophysical research communications.

[26]  Dean Y. Li,et al.  roundabout4 is essential for angiogenesis in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Y. Taketani,et al.  Possible implication of midkine in the development of endometriosis. , 2005, Human reproduction.

[28]  D. Nettelbeck,et al.  Evaluation of tumor-specific promoter activities in melanoma , 2005, Gene Therapy.

[29]  D. Curiel,et al.  Gene transfer to cervical cancer with fiber‐modified adenoviruses , 2004, International journal of cancer.

[30]  D. Nettelbeck,et al.  Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy. , 2004, Human gene therapy.

[31]  C. Rancourt,et al.  Quantitative assessment of human endometriotic tissue maintenance and regression in a noninvasive mouse model of endometriosis. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  B. Liu,et al.  Transcriptional targeting of tumors with a novel tumor-specific survivin promoter , 2004, Cancer Gene Therapy.

[33]  D. Nettelbeck,et al.  Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter , 2004, Gene Therapy.

[34]  A. Hemminki,et al.  Transductional and transcriptional targeting of adenovirus for clinical applications. , 2004, Current gene therapy.

[35]  L. Giudice.  Genomics' Role in Understanding the Pathogenesis of Endometriosis , 2003, Seminars in reproductive medicine.

[36]  B. Liu,et al.  The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy , 2003, The journal of gene medicine.

[37]  C. Dabrosin,et al.  Therapeutic effect of angiostatin gene transfer in a murine model of endometriosis. , 2002, The American journal of pathology.

[38]  D. Curiel,et al.  Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. , 2002, Human gene therapy.

[39]  Y. Hung,et al.  Survivin gene expression in endometriosis. , 2002, The Journal of clinical endocrinology and metabolism.

[40]  C. Librach,et al.  Immunohistochemical analysis of alphavbeta5 and alphavbeta6 integrins in the endometrium and endometriosis. , 2002, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[41]  Y. Wen,et al.  Pleiotrophin (PTN) and midkine (MK) mRNA expression in eutopic and ectopic endometrium in advanced stage endometriosis. , 2002, Molecular human reproduction.

[42]  M. Gore,et al.  Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  A. Starzinski-Powitz,et al.  Identification of an invasive, N-cadherin-expressing epithelial cell type in endometriosis using a new cell culture model. , 2001, The American journal of pathology.

[44]  R. Alemany,et al.  Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[45]  S. Igarashi,et al.  Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. , 2001, Human reproduction.

[46]  D. Curiel,et al.  Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors. , 2000, Cancer research.

[47]  T. Hermiston.  Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. , 2000, The Journal of clinical investigation.

[48]  T. McDonnell,et al.  A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo , 2000, Oncogene.

[49]  R. Garry,et al.  The effect of endometriosis and its radical laparoscopic excision on quality of life indicators , 2000, BJOG : an international journal of obstetrics and gynaecology.

[50]  N. Suzumori,et al.  Expression of secretory leukocyte protease inhibitor in women with endometriosis. , 1999, Fertility and sterility.

[51]  S. Litvinov,et al.  The biology of the 17–1A antigen (Ep-CAM) , 1999, Journal of Molecular Medicine.

[52]  C. Miller,et al.  An Adenovirus Vector with Genetically Modified Fibers Demonstrates Expanded Tropism via Utilization of a Coxsackievirus and Adenovirus Receptor-Independent Cell Entry Mechanism , 1998, Journal of Virology.

[53]  D. Brough,et al.  Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins , 1997, Journal of virology.

[54]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[55]  M. Canis,et al.  Revised American Society for Reproductive Medicine classification of endometriosis: 1996. , 1997, Fertility and sterility.

[56]  J. Bergelson,et al.  Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5 , 1997, Science.

[57]  A. Fattaey,et al.  An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.

[58]  D. Curiel,et al.  Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism , 1996, Journal of virology.

[59]  I. Pastan,et al.  Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[60]  J. Hill,et al.  Immunology and endometriosis. , 1992, Fertility and sterility.

[61]  H. Rosenkranz,et al.  Structure and Development of Viruses as Observed in the Electron Microscope , 1969, Journal of virology.

[62]  H. M. Rose,et al.  STRUCTURE AND DEVELOPMENT OF VIRUSES AS OBSERVED IN THE ELECTRON MICROSCOPE , 1961, The Journal of experimental medicine.

[63]  Treatment of pelvic pain associated with endometriosis. , 2006, Fertility and sterility.

[64]  A. Birmingham,et al.  The Practice Committee of the American Society for Reproductive Medicine and the Practice Committee of the Society for Assisted Reproductive Technology , 2006 .

[65]  D. Curiel,et al.  Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy , 2005, Gene Therapy.

[66]  D. Curiel,et al.  Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[67]  C. Librach,et al.  Immunohistochemical Analysis of v 5 and v 6 Integrins in the Endometrium and Endometriosis , 2002 .

[68]  H. M. Rose,et al.  Structure and development of viruses as observed in the electron microscope. 8. Entry of influenza virus. , 1968, Journal of virology.